News and Trends 7 Feb 2017 Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson’s. An international team of top European biotech investors has participated in Prexton Therapeutics’ latest financing round. The €29M Series B round was co-led by the Dutch Forbion and the Irish Seroba Life Sciences, […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2017 French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […] February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 6 Feb 2017 “We want to be the Worldwide Leader in Microbiota” Biotech entrepreneur Hervé Affagard, CEO of MaaT Pharma, tells the story behind the success of his young microbiome company. Hervé Affagard is the CEO and co-founder of a company with an ambitious goal: become the global leader in treating the gut microbiota. Founded in 2014 and based in Lyon, MaaT pharma wants to employ fecal transplants to treat […] February 6, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Feb 2017 This PhD-Carrying Musician Tells the Story of Life through Music & Video Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […] February 4, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2017 Could GM Insects impact the international trade of Organic Food? Genetically modified insects are released to control the spread of diseases and crop pests, but the logistics may not be so simple: these little creatures could jam global food exports, particularly to more GM-averse Europe. What happens when genetically engineered insects develop on vegetable farms? Two researchers, from the Max Planck Institue for Evolutionary Biology in […] February 3, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 2 Feb 2017 Galapagos kicks off a Phase IIa trial for Cystic Fibrosis After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […] February 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Young Belgian Biotech will tackle Fibrosis with a New Grant Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Meet these 3 Exciting German Startups Pitching in Aachen Today! Today is Life Science Pitch Day in Aachen! High-Tech Gründerfonds has invited a handful of startups in the seed and Series A stages to make their pitches to investors this afternoon. Here are three of the companies who you’ll hear speak! cytena cytena, a spinoff from the University of Freiburg, is improving current methods in […] February 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Young German Immune Therapy Biotech expands its Series A Funding Immunic Therapeutics has received an extra €4M that will be directed at speeding the development of treatments for Crohn’s disease and psoriasis. Immunic Therapeutics is a young company based in Munich’s biotech hub that develops immune therapies for chronic inflammatory diseases. Today, it announced a €4M investment from IBG, which increases its Series A financing to a […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium, develops stem cell therapies derived from donors. This morning, the first patient was treated in a Phase Ib/IIa clinical trial for its candidate therapy Cx611 in […] February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 New British Biotech-Academia Alliance takes on Cardiovascular Disease Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 Top 5 Biologicals from European Biopharma to Launch in 2017 A new report listing the top drug launches this year reveals the strong performance of biologicals and European biopharma on the drug market. After the worst year in biotech finance, experts seem to agree that the industry will start recovering in 2017. There are still substantial uncertainties, mostly regarding the new US administration. Though a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email